November 1st, 2022 
The global dry powder inhaler devices market was valued at USD 13,935 million in 2021, growing at a CAGR of 4.58% during the forecast period from 2022 to 2027 to reach USD 18,626 million by 2027.
The dry powder inhaler devices market is witnessing a positive growth owing to the various factors such as increasing prevalence of COVID-19, rising prevalence of diabetes, increasing prevalence of asthma, surge in cystic fibrosis cases, surge in prevalence of Chronic Obstructive Pulmonary Diseases (COPD), rise in geriatric population and increase in technological advancements with respect to the product offerings. Therefore, the dry powder inhaler devices market is estimated to grow during the forecast period from 2022 to 2027.
Some of the key market players operating in the Dry powder inhaler devices market include Boehringer Ingelheim Inc, CHIESI Farmaceutici S.p.A, Cipla Inc, GSK Group of Companies, Hovione, OPKO Health Inc, Teva Pharmaceutical Industries Ltd, Vectura Group Ltd, Radius Innovation & Development, Otsuka Pharmaceutical Co Ltd, RESPIRA THERAPEUTICS INC, MannKind Corporation, Pharmaxis Ltd, Stevanato Group, Harro Höfliger Verpackungsmaschinen GmbH, H&T Presspart Manufacturing Ltd, Catalent Inc, Merxin Ltd, Manta Devices LLC, PUREIMS, and among others.
if (screen_width <= 991) {
(function() {
var a="",b=[
"adid=medg-medgadget-poster",
"site=ehs.pro.medg.medgadget",
"size=300×250",
"vpos=t",
"hpos=r",
"zone=",
];
for (var c=0;c<b.length;++c){a+=b[c]+"&";}a+="url="+encodeURIComponent(window.location.href);
var x="https://ads.ehealthcaresolutions.com/a/?"+a;
var y=document.createElement("script");y.type="text/javascript";y.async=true;y.src=x;
var z=document.getElementsByTagName("script")[0];
z.parentNode.insertBefore(y, z);
})();
}
DelveInsight’s “Dry Powder Inhaler Devices Market Insight & Forecast” report will offer an in-depth understanding of the Dry Powder Inhaler Devices market, further benefiting the competitors or stakeholders operating in the Dry Powder Inhaler Devices arena.
A Dry-Powder Inhaler is a device that uses dry powder to deliver medicine to the lungs. DPIs are often used to treat respiratory disorders such as asthma, bronchitis, emphysema, and COPD, but they have also been used to treat diabetes mellitus.
Interested to know more about the functioning of Dry Powder Inhaler Devices- Visit @ Dry Powder Inhaler Devices Operations & Working.
Among all the regions, North America is expected to dominate the global dry powder inhaler devices market in the year 2021 and is expected to do the same during the forecast period from 2022-2027. Factors such as the rising prevalence of COVID-19 and surge in cystic fibrosis cases are expected to increase the demand of dry powder inhaler devices in the North American market.
According to the data published by WHO from 3 January 2020 to 21 September 2022, there have been 94,471,064 confirmed cases of COVID-19 in United States. Further, COVID-19 increased the respiratory infections in the patients affecting the lungs. Thus, rising prevalence of COVID increased the demand for dry powder inhaler devices, which surged the growth for dry powder inhaler devices overall market forecast.
Moreover, as per the latest data released by American Lung Association in the year 2020, cystic fibrosis affected approximately 30,000 people in the United States. Also, as per cystic fibrosis Canada’s 2020 annual data report from the Canadian Cystic Fibrosis Registry, had released that in 2020, there were 4,332 Canadians with CF, with 62 percent of them being adults. Further, dry powder inhalers are available for the treatment of cystic fibrosis. Therefore, surge in cystic fibrosis cases would increase the demand for dry powder inhaler devices, which boost the dry powder inhaler devices overall market growth.
Furthermore, the factors mentioned above, provide a conducive growth environment for North American region in dry powder inhaler devices market.
To read more about why North America is leading the market growth in the Dry Powder Inhaler Devices market, get a snapshot of the Dry Powder Inhaler Devices market report.
One of the main drivers of the dry powder inhaler devices market is the rising prevalence of diabetes. For instance, according to the International Diabetes Federation (IDF), IDF Diabetes Atlas Tenth edition released in the year 2021, worldwide, diabetes affected roughly 537 million people of age between 20-79 years. By the year 2030, the overall number of diabetes is expected to reach 643 million, and by 2045, it will reach 783 million. Thus, dry powder inhaler are used to treat diabetes by using insulin powder. Therefore, rising diabetes cases increases the demand of dry powder inhaler devices, which drives the overall dry powder inhaler devices market forward over the forecast period (2022-2027).
Moreover, another key factor which is responsible for the growth of dry powder inhaler devices market is the increasing prevalence of asthma. For instance, according to World Health Organization (WHO) published data in the year 2022, asthma affected 262 million people in 2019 worldwide. Further, dry powder inhaler devices are used to deliver asthma medication to the lungs, thus increasing prevalence of asthma increases the demand for dry powder inhaler devices, which leads to a surge in the dry powder inhaler devices market during the forecast period.
However, lack of awareness about dry powder inhaler devices and disadvantages associated with the devices, can hamper the global dry powder inhaler devices market growth.
The COVID-19 pandemic has positively impacted the market for dry powder inhaler devices, this can be anticipated owing to the severe effects of COVID-19 on lungs and COVID-19 patients that had suffered with respiratory infections as an after effect of COVID-19, as well as shortness of breath as its prevalent symptom, had also contributed to the dry powder inhaler devices demand among COVID-19 patients. Hence, the demand for dry powder inhaler devices will continue to rise in the forecast period from 2022-2027.
Some of the key market players operating in the Dry powder inhaler devices market include Boehringer Ingelheim Inc, CHIESI Farmaceutici S.p.A, Cipla Inc (NSE: CIPLA), GSK Group of Companies, Hovione, OPKO Health Inc (NASDAQ:OPK), Teva Pharmaceutical Industries Ltd (TLV: TEVA), Vectura Group Ltd, Radius Innovation & Development, Otsuka Pharmaceutical Co Ltd (OTSKF), RESPIRA THERAPEUTICS INC, MannKind Corporation (MNKD), Pharmaxis Ltd (PMXSF), Stevanato Group (NYSE:STVN), Harro Höfliger Verpackungsmaschinen GmbH, H&T Presspart Manufacturing Ltd, Catalent Inc, Merxin Ltd, Manta Devices LLC, PUREIMS, and among others.
Table of Contents
To understand key companies related to the Dry Powder Inhaler Devices Market, get a snapshot of the Dry Powder Inhaler Devices Regulatory and Patent Analysis.
Learn More About DelveInsight Report Offerings:
Trending Healthcare Blogs by DelveInsight:
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Get in touch with our team to get more detailed insights into how the MedTech Market is expected to advance in the coming years and formulate innovative business solutions at MedTech Consulting Solutions.
Contact Us
Kritika Rehani
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com
Sign up and submit a press release
Medical technologies transform the world! Join us and see the progress in real time. At Medgadget, we report the latest technology news, interview leaders in the field, and file dispatches from medical events around the world since 2004.